thiotepa has been researched along with Minimal Disease, Residual in 5 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| " In order to decrease nonrelapse mortality, and enhance the graft-versus-tumor effect, a program was designed in which a reduced conditioning with thiotepa, fludarabine, and cyclophosphamide was associated with programmed reinfusions of donor lymphocytes for patients without graft-versus-host disease (GVHD), not achieving clinical and molecular remission after transplantation." | 3.71 | Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. ( Benedetti, F; Bordignon, C; Bregni, M; Ciceri, F; Corradini, P; Dodero, A; Falda, M; Gianni, AM; Ladetto, M; Lucesole, M; Olivieri, A; Pileri, A; Rambaldi, A; Sajeva, MR; Tarella, C; Tresoldi, M; Voena, C; Zallio, F, 2002) |
| "Temozolomide was administered twice daily on days -10 to -6, followed by thiotepa 300 mg/m(2) per day and carboplatin dosed using the Calvert formula or body surface area on days -5 to -3, with AHCR day 0." | 2.82 | Phase I study of temozolomide in combination with thiotepa and carboplatin with autologous hematopoietic cell rescue in patients with malignant brain tumors with minimal residual disease. ( Belasco, JB; Cervone, KA; Egan, G; Finlay, JL; Gardner, SL; Philips, PC, 2016) |
| "Close to 75% of all bladder tumors are confined to the urothelium (stage Ta, or carcinoma in situ), and nearly 30% of papillary tumors invade the lamina propria (stage T1)." | 2.41 | Intravesical therapy for superficial bladder cancer. ( Baselli, EC; Greenberg, RE, 2000) |
| "The load of minimal residual disease prior to transplantation appears to be predictive for outcome in this very poor-prognosis subgroup of ALL." | 1.33 | Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children. ( Escherich, G; Hassenpflug, WA; Horstmann, MA; Janka, G; Kabisch, H; zur Stadt, U, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Egan, G | 1 |
| Cervone, KA | 1 |
| Philips, PC | 1 |
| Belasco, JB | 1 |
| Finlay, JL | 1 |
| Gardner, SL | 1 |
| Horstmann, MA | 1 |
| Hassenpflug, WA | 1 |
| zur Stadt, U | 1 |
| Escherich, G | 1 |
| Janka, G | 1 |
| Kabisch, H | 1 |
| Kanteti, R | 1 |
| Miller, K | 1 |
| McCann, J | 1 |
| Roitman, D | 1 |
| Morelli, J | 1 |
| Hurley, C | 1 |
| Berkman, E | 1 |
| Schenkein, D | 1 |
| Baselli, EC | 1 |
| Greenberg, RE | 1 |
| Corradini, P | 1 |
| Tarella, C | 1 |
| Olivieri, A | 1 |
| Gianni, AM | 1 |
| Voena, C | 1 |
| Zallio, F | 1 |
| Ladetto, M | 1 |
| Falda, M | 1 |
| Lucesole, M | 1 |
| Dodero, A | 1 |
| Ciceri, F | 1 |
| Benedetti, F | 1 |
| Rambaldi, A | 1 |
| Sajeva, MR | 1 |
| Tresoldi, M | 1 |
| Pileri, A | 1 |
| Bordignon, C | 1 |
| Bregni, M | 1 |
1 review available for thiotepa and Minimal Disease, Residual
| Article | Year |
|---|---|
Intravesical therapy for superficial bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Anticarcinogenic | 2000 |
2 trials available for thiotepa and Minimal Disease, Residual
| Article | Year |
|---|---|
Phase I study of temozolomide in combination with thiotepa and carboplatin with autologous hematopoietic cell rescue in patients with malignant brain tumors with minimal residual disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Brain Neoplasms; Carb | 2016 |
Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Bone Ma | 1999 |
2 other studies available for thiotepa and Minimal Disease, Residual
| Article | Year |
|---|---|
Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Comb | 2005 |
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Cyclophosphamide; Cyclosporine; Female; Graf | 2002 |